The Law Offices of Frank R. Cruz reminds investors of the upcoming October 21, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired DexCom, Inc. ...

DexCom's key Q3 earnings factors include Stelo sales, updates on sales channels, and potential share buybacks. See why I ...

The Gross Law Firm Notifies Shareholders of DexCom, Inc.(DXCM) of a Class Action Lawsuit and an Upcoming Deadline ...

On Tuesday, DexCom Inc (DXCM) stock saw a decline, ending the day at $67.1 which represents a decrease of $-2.08 or -3.01% from the prior close of $69.18. The stock opened at $69 and touched a low of ...

Artisan Partners, an investment management company, released its “Artisan Mid Cap Fund” third quarter 2024 investor letter. A ...

Investors and analysts reacted immediately to DexCom's revelation. The price of DexCom's common stock declined dramatically.

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that securities class action lawsuits have been filed ...

A top healthcare stock to own over the years has been DexCom (DXCM 1.18%). The company makes continuous glucose monitors ...

We recently made a list of Piper Sandler’s Top Technical Stock Picks: 20 Best Stocks. In this piece, we will look at where ...

Today, DexCom is the leading CGM company, with an estimated 40% market share. Importantly, CGM products are relatively nascent. DexCom generates nearly $4 billion in annual sales on a user base of ...

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Diabetes is a global epidemic, with more than 537 million people affected worldwide. DexCom (NASDAQ: DXCM) has improved patient lives with technology, and the stock has outperformed the stock ...